Sera Prognostics, Inc. Class A Common Stock (SERA)
Sera Prognostics, Inc. Class A (SERA) is a biotechnology company focused on developing maternal-fetal health diagnostics. The firm specializes in creating tests aimed at predicting the risk of preterm birth and other pregnancy complications, leveraging proteomic and biomarker analysis to improve maternal and neonatal outcomes.
Company News
Elevance Health's (ELV) performance benefits from new contract wins, a strong Carelon segment and recovering Medicaid business.
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings. Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billion. Excluding an item resulted in an increase of $550 million (after tax) to reported net income from $13.4 billion to $14.0 billion and an incre...
Debunking common myths about trading penny stocks in 2023 The post 3 Common Myths About Penny Stocks Debunked appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
SERA earnings call for the period ending June 30, 2022.
Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy